VistaGen Therapeutics, Inc. (VSTA) Continues To Grow Key Partnerships
VistaGen, developers of a unique stem-cell based bioassay platform for use in the early identification and elimination of toxicity issues during drug development, plans to use their technology to create a valuable pipeline of drug rescue variants. The company is targeting new drugs that have shown significant potential, but which have been shelved due to heart or liver toxicity issues. VistaGen can effectively rescue those drugs, using their proprietary bioassay technology to help economically solve the toxicity problems, thereby benefitting from all of the research that went into developing the drugs in the first place. The profit potential is enormous, but VistaGen recognizes the critical importance of cultivating strong partnerships to help them realize this strategic goal.
Two of VistaGen's less publicized but key partnerships and supporters are the National Institutes of Health and the Wisconsin Alumni Research Foundation.
• National Institutes of Health (NIH) - The NIH is the largest source of funding for medical research in the world, made up of 27 institutes and centers. For over a century, NIH scientists have paved the way for important discoveries that improve health and save lives. The medical research agency has created hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions in every state across America and around the globe. To date, VistaGen has been awarded over $8.5 million from NIH.
• Wisconsin Alumni Research Foundation (WARF) - Since its founding in 1925, the Wisconsin Alumni Research Foundation (WARF) has served the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States, and worldwide. They promote, encourage, and aid scientific investigation and research at the University of Wisconsin-Madison and the Morgridge Institute for Research through helping commercialize the technology arising from that research.
For additional information, visit VistaGen.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.